View : 241 Download: 60
Increased serum levels of mutant p53 proteins in patients with colorectal cancer
- Increased serum levels of mutant p53 proteins in patients with colorectal cancer
- Shim K.-S.; Kim K.-H.; Park B.-W.; Lee S.-Y.; Choi J.-H.; Han W.-S.; Park E.-B.
- Ewha Authors
- 한운섭; 박응범; 김광호; 이선영
- SCOPUS Author ID
- 한운섭; 박응범; 김광호; 이선영
- Issue Date
- Journal Title
- Journal of Korean Medical Science
- Journal of Korean Medical Science vol. 13, no. 1, pp. 44 - 48
- SCI; SCIE; SCOPUS; KCI
- Document Type
Show the fulltext
- We have examined the serum levels of the mutant p53 protein in patients with colorectal cancer preoperatively (n=50), and in patients with adenomatous polyp (n=13). Mutant p53 protein in patients after curative surgical resection of colorectal cancer (n=26, part of the fifty preoperative patients) was also measured. Serum samples were stored frozen at -70°C until the time of analysis. We used the p53 mutant ELISA (QIA03, CALBIOCHEM) system. Serum levels of the mutant p53 protein in patients with colorectal cancer (mean=0.97±0.14 ng/ml, ranged from 0.7 ng/ml to 1.37 ng/ml, n=50) were significantly greater than those in patients with adenomatous polyp (mean=0.73±0.06 ng/ml, ranged from 0.69 ng/ml to 0.83 ng/ml) (p<0.001). There was a significant correlation between serum p53 levels and CA19-9 levels (p<0.01). Serum levels of the mutant p53 protein prior to surgery (mean=0.97±0.13 ng/ml, n=26) significantly decreased after surgical resection of tumor (mean=0.82±0.07 ng/ml) (p<0.001, paired t-test). These results suggest that mutant p53 protein might be used as a potential biomarker in the management of patients with colorectal cancer. Further study is warranted to establish its clinical significance. Copyright © The Korean Academy of Medical Sciences.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
Increased serum levels.pdf(648.56 kB)
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.